Inside the Breakthroughs That Changed Melanoma Care

For decades advanced melanoma was one of the most difficult cancers to treat. Options were limited and outcomes were grim. 

That began to change in 2011, when two landmark therapies, ipilimumab and vemurafenib, received approval from the U.S. Food and Drug Administration, bringing a new era of immunotherapy and targeted treatment. 

Researchers at Moffitt Cancer Center played a key role in bringing those therapies, and many that followed, from clinical trials to patients. 

A Defining Moment in 2011 

The approval of ipilimumab, the first immune checkpoint inhibitor to improve survival in metastatic melanoma, marked a turning point for the field. Moffitt researchers contributed to the pivotal clinical trial, with the late Jeff Weber, MD, serving as an author on the landmark study published in the New England Journal of Medicine. 

Keiran Smalley, PhD

At the same time, vemurafenib introduced a new precision approach, targeting tumors with specific BRAF mutations. 

“Before 2011, the average survival for stage 4 melanoma patients was less than six months,” said Keiran Smalley, PhD, director of Moffitt’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence. “Now we have multiple FDA-approved targeted therapies and immunotherapies, and five-year survival is up to around 35%. People used to think advanced melanoma was a death sentence. That is no longer true.” 

A Consistent Role in FDA Approvals 

Since that inflection point, Moffitt has maintained a steady presence in the development of new melanoma therapies, playing a role in every melanoma FDA approval to date, according to Smalley. 

That includes major advances in both immunotherapy and targeted treatment. Moffitt scientists helped lay the groundwork for BRAF-MEK inhibitor combinations, providing early preclinical evidence that pairing the therapies could improve outcomes. The institution later contributed to the clinical trials that led to their approval. 

Researchers at Moffitt have also helped advance newer approaches, including tumor-infiltrating lymphocyte, or TIL therapy, and percutaneous hepatic perfusion for uveal melanoma. 

Together, these efforts reflect a long-standing commitment to translating scientific discoveries into treatments that reach patients.

The FDA approves a new cancer therapy that could one day transform the way a majority of aggressive and advanced tumors are treated. https://t.co/WbhqF1WbBm

— NBC News (@NBCNews) February 16, 2024

Progress and Persistent Challenges 

Despite significant gains, not all patients benefit from current therapies. Understanding why remains a central focus of research. 

“Melanoma cells are incredibly adaptable,” Smalley said. “With targeted therapies, they can acquire new mutations or reprogram themselves in ways that allow them to escape treatment. They are also very good at avoiding immune recognition.” 

This ability to evolve and resist therapy has driven ongoing research into combination approaches and next-generation treatments designed to overcome resistance. 

Choosing the Right Treatment 

With a growing number of FDA-approved therapies available, clinicians now face a different challenge: determining how best to use them. 

“If a patient has time, immunotherapy is usually the first approach because it offers the best chance for long-term benefit or cure,” Smalley said. “For patients with BRAF-mutant melanoma, targeted therapy is often used if immunotherapy does not work or if the disease is progressing quickly.” 

This sequencing strategy reflects years of clinical research and continues to evolve as new data emerge. 

Looking Ahead 

The pace of innovation in melanoma treatment shows no signs of slowing. Researchers are exploring a new generation of therapies aimed at further improving outcomes and expanding options for patients. 

“There is a lot of exciting work happening with melanoma vaccines, as well as T-cell receptor (TCR )therapy and other cellular therapies,” Smalley said. “The success of TIL therapy has really opened the door for a new generation of treatments.” 

On the targeted therapy side, new approaches are also on the horizon. 

“We are excited about RAS-ON inhibitors,” he added. “These have shown promise in other cancers, and we think they could be effective in NRAS-mutant melanoma as well.” 

What was once considered an almost uniformly fatal disease has been transformed into one where long-term survival and even cure is possible for some patients. 

That progress is the result of decades of research, collaboration and clinical trials, many of them involving Moffitt investigators. 

As new therapies continue to move from the lab to the clinic, the goal remains clear: to build on that momentum and bring even more effective treatments to patients facing melanoma.